Tags:Science & Tech
Source:
Hindustan
Subject: Health and Social Sector, Diseases and Public Health Interventions
Key points for Prelims: Human papillomavirus (HPV), International Agency for Research on Cancer (IARC), Cervical cytology and colposcopy, WHO elimination campaign for cervical cancer (2020), Risk-based screening
Mains syllabus mapping
- General Studies Paper 2: Health: Issues relating to health, diseases and interventions; role of international organisations such as WHO and IARC
- General Studies Paper 3: Science and technology: developments in biotechnology and health-related diagnostics; public health and healthcare resource allocation
Key facts for one-day exams
- The IARC study covered more than 44,000 women.
- Participants were aged 30-64 years.
- The study included nine Latin American countries.
- The reported risk among HPV-negative women was 0.04%.
- The World Health Organization started its cervical cancer elimination campaign in 2020.
Cervical cancer risk assessment study: why in the news?
A large international study published in The Lancet Regional Health has shown that combining HPV testing, cervical cytology and colposcopy can improve risk assessment for cervical cancer, which could help prioritise treatment in resource-limited settings.
A study of more than 44,000 women across nine Latin American countries has found that combining human papillomavirus (HPV) testing, cervical cytology and colposcopy can improve the assessment of cervical cancer risk. The research was conducted by the International Agency for Research on Cancer (IARC), the specialised cancer agency of the World Health Organization, and its collaborators, and was published in The Lancet Regional Health.
The study included women aged 30 to 64 years from Argentina, Bolivia, Colombia, Costa Rica, Honduras, Mexico, Paraguay, Peru and Uruguay. Researchers analysed the results of HPV tests, cervical cytology and colposcopy. Among women who tested HPV-positive, the reported risk of severe cervical precancer or cancer was 12%. In contrast, among women who tested HPV-negative, the risk was 0.04%.
Dr Joanne Valls, a co-author of the study, said that combining the results of different tests can help doctors decide which women need immediate biopsy or treatment and which can be kept on routine follow-up. Dr Partha Basu of IARC said that most deaths from cervical cancer occur in low- and middle-income countries, and that the research will help use limited health resources to identify women at higher risk in time and save lives.
Globally, an estimated 660,000 new cases of cervical cancer and 350,000 deaths occur each year, with more than 90% of deaths in low- and middle-income countries. The World Health Organization started an elimination campaign in 2020. Modern medical guidelines are moving towards risk-based assessment, which considers a woman's current HPV and cytology results along with her previous screening and treatment history, rather than relying on age or a single test alone.
What is the WHO cervical cancer elimination strategy?
The World Health Organization launched the Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem in 2020. The strategy sets 2030 targets for HPV vaccination, screening and treatment of cervical disease. The International Agency for Research on Cancer, based in Lyon, France, is the specialised cancer agency of the World Health Organization. Cervical cancer is caused mainly by persistent infection with high-risk types of the human papillomavirus. The WHO recommends HPV DNA testing as the primary screening method for cervical cancer in the general population of women.
What is the background of cervical cancer screening?
Cervical cancer affects the cervix, and screening can identify abnormalities before cancer develops. The World Health Organization started an elimination campaign in 2020. HPV vaccination, timely screening and treatment are important prevention measures. The principle of equal management for equal risk informs treatment decisions based on a woman's risk level rather than age or a single test alone. A 2019 approach used data from more than 1.5 million women to guide risk-based management, incorporating present findings and relevant medical history.
How does the study improve risk assessment?
The study analysed results from over 44,000 women aged 30-64 in nine Latin American countries. The reported risk of severe cervical precancer or cancer differed substantially by HPV result: 12% for positive and 0.04% for negative tests. Combining test results may refine decisions about biopsy, treatment and follow-up. Risk-based care can use current HPV and cytology results together with previous screening and treatment history. In settings with limited resources, prioritising women at higher risk for timely investigation while maintaining follow-up for others may improve allocation.
What is the global burden and equity challenge?
An estimated 660,000 new cervical cancer cases and 350,000 deaths occur globally each year. Over 90% of the deaths occur in low- and middle-income countries. The distribution makes timely identification and access to appropriate treatment particularly important where health resources are constrained. Vaccination, screening access and treatment remain complementary components of prevention.
Reported risk by HPV test result
| HPV result | Reported risk |
|---|---|
| Positive | 12% |
| Negative | 0.04% |
Key terms
- Cervical cytology:
- Examination of cells from the cervix to identify abnormal changes.
- Colposcopy:
- Examination of the cervix using a magnifying instrument to identify abnormal areas.
- Biopsy:
- Removal of a small tissue sample for laboratory examination.
- International Agency for Research on Cancer:
- The specialised cancer research agency of the World Health Organization.
Cervical cancer risk assessment study: why it matters for exams
Syllabus: Science and Technology: Disease prevention and diagnostic tests; Society: Public health and access to healthcare
Common mistake: Examiners may present the 12% risk as applying to HPV-negative women; it applies to HPV-positive women, while the reported risk for HPV-negative women was 0.04%.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Risk-based assessment of cervical cancer, combining HPV testing, cytology and colposcopy, is being promoted over age-based or single-test screening. Critically examine how such an approach can strengthen public health delivery in low- and middle-income countries, and what constraints may limit its implementation.
Answer outline
- Introduction: Open by noting that a study of over 44,000 women across nine Latin American countries found combined testing improves risk assessment, and that most cervical cancer deaths occur in low- and middle-income countries.
- Body:
- Explain how combining HPV results (12% risk among HPV-positive versus 0.04% among HPV-negative) helps target immediate biopsy or treatment and avoid unnecessary intervention.
- Highlight benefits: efficient use of limited health resources, earlier identification of high-risk women, reduced cancer deaths, and alignment with WHO's 2020 elimination campaign.
- Discuss constraints: shortage of trained colposcopists, laboratory and cold-chain infrastructure, cost of HPV tests, and difficulty in ensuring follow-up of women in rural or remote areas.
- Note the role of the prior screening and treatment history in risk-based models and the need for reliable health records and data systems.
- Mention the need for community awareness, vaccination coverage and integration with primary health care to sustain the programme.
- Conclusion: A risk-based, multi-test strategy can make cervical cancer screening more precise and affordable, but its success depends on building workforce, laboratory capacity and follow-up systems alongside HPV vaccination and awareness.
Question 2(GS-2 | 150 words | 10 marks)
Discuss how international agencies such as the WHO and IARC contribute to tackling non-communicable and infectious disease burdens in developing countries, using the cervical cancer research as an illustration.
Answer outline
- Introduction: Mention that IARC, the cancer agency of the WHO, together with regional collaborators produced a multi-country study on cervical cancer published in The Lancet Regional Health.
- Body:
- Evidence generation: multi-country studies provide data on risk and testing performance that guide national guidelines.
- Global norm-setting: WHO's 2020 elimination campaign sets targets and mobilises countries towards common goals.
- Resource prioritisation: research helps low- and middle-income countries use limited funds on high-risk women.
- Capacity building and knowledge sharing across regional partners.
- Conclusion: International agencies bring research, standards and coordination that national governments can adapt, but sustained domestic financing and health system strengthening remain essential for results.
Stuck? Get it in one tap
Cervical cancer screening looks for infection or abnormal changes in the cervix. HPV testing checks for human papillomavirus, while cytology examines cervical cells and colposcopy examines the cervix under magnification. Combining results can help doctors decide who needs further investigation or routine follow-up.
- Science and Technology: Disease prevention and diagnostic tests
- Society: Public health and access to healthcare
Related concepts: Cervical cytology, Colposcopy, Biopsy, International Agency for Research on Cancer
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
Which organisation is the parent body of the International Agency for Research on Cancer?
Explanation: The International Agency for Research on Cancer is the cancer research agency of the World Health Organization. UNICEF, UNFPA and the World Bank are not its parent body.
- Q2Hard
Consider the following statements about the IARC cervical cancer study:
- 1. The study covered women aged 30-64 years.
- 2. The study covered nine Latin American countries.
- 3. The reported risk of severe cervical precancer or cancer was higher among HPV-negative women than among HPV-positive women.
Which of the statements given above are correct?
Explanation: Statements 1 and 2 are correct: the study included women aged 30-64 across nine Latin American countries. Statement 3 is incorrect: the reported risk was 12% among HPV-positive women and 0.04% among HPV-negative women.
- Q3Medium
What risk of severe cervical precancer or cancer was reported among HPV-negative women in the IARC study?
Explanation: The reported risk among HPV-negative women was 0.04%. The figure of 12% applied to HPV-positive women; 0.4% and 4% are different values.
- Q4Medium
Why can combining HPV testing, cervical cytology and colposcopy results improve cervical cancer care?
Explanation: Combining results can support decisions on biopsy, treatment or follow-up according to risk. Previous history and vaccination remain relevant, and an HPV-positive result is not equivalent to a cancer diagnosis.
Frequently asked questions
1. How many women were included in the IARC cervical cancer study?
More than 44,000 women aged 30-64 years were included across nine Latin American countries.
2. Which tests were combined in the cervical cancer risk study?
The study analysed HPV testing, cervical cytology and colposcopy results together.
3. What risk was reported for HPV-positive women in the IARC study?
The reported risk of severe cervical precancer or cancer was 12% among HPV-positive women.
4. When did WHO start its cervical cancer elimination campaign?
The World Health Organization started the campaign in 2020.
All sources
Original17 November 2026 · Read story

